{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T04:52:22Z","timestamp":1784868742649,"version":"3.55.0"},"reference-count":18,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T00:00:00Z","timestamp":1636329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and prognostic information is essential in finding the right treatment. This study evaluated the prognostic significance of Ki-67 in patients with DLBCL. Methods: Patients with DLBCL, treated with first-line R-CHOP, were retrospectively analyzed in groups of high (&gt;70%) and low (\u226470%) Ki-67. Parameters of interest were the international prognostic index (IPI), treatment response, progression-free survival (PFS) and overall survival (OS). A chi-squared test or Fisher\u2019s exact test was conducted to analyze categorical variables. Kaplan\u2013Meier and log-rank tests were applied for survival analyses. Finally, a multivariate linear regression analysis was performed, including gender, Ki-67 \u2264 70% or &gt;70%, IPI and presence of B symptoms. Results: Overall, 58 patients were included. No significant association was found between Ki-67 status and IPI (p = 0.148) or treatment response (p = 0.373). Survival in patients with high Ki-67 was significantly inferior with respect to OS (p = 0.047) but not PFS (p = 0.138). Multivariate linear regression, however, yielded only IPI as a risk factor for OS. Conclusion: Future studies with larger patient cohorts are needed in order to elucidate the prognostic role of Ki-67 in patients with DLBCL treated with R-CHOP.<\/jats:p>","DOI":"10.3390\/curroncol28060383","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T22:08:41Z","timestamp":1636409321000},"page":"4521-4529","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Evaluation of Ki-67 as a Prognostic Marker in Diffuse Large B-Cell Lymphoma\u2014A Single-Center Retrospective Cohort Study"],"prefix":"10.3390","volume":"28","author":[{"given":"Fabian","family":"Huber","sequence":"first","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Zwickl-Traxler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine 2, University Hospital Krems, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Pecherstorfer","sequence":"additional","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, 3500 Krems, Austria"},{"name":"Department of Internal Medicine 2, University Hospital Krems, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-2412","authenticated-orcid":false,"given":"Josef","family":"Singer","sequence":"additional","affiliation":[{"name":"Karl Landsteiner University of Health Sciences, 3500 Krems, Austria"},{"name":"Department of Internal Medicine 2, University Hospital Krems, 3500 Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,8]]},"reference":[{"key":"ref_1","first-page":"291","article-title":"Diffuse large B-cell lymphoma","volume":"Volume 2","author":"Swerdlow","year":"2017","journal-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-14-153","article-title":"Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: Evidence from a systematic meta-analysis","volume":"14","author":"He","year":"2014","journal-title":"BMC Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s12185-014-1719-3","article-title":"High Ki-67 expression in involved bone marrow predicts worse clinical outcome in diffuse large B cell lymphoma patients treated with R-CHOP therapy","volume":"101","author":"Song","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1600-0609.2012.01778.x","article-title":"High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy","volume":"88","author":"Li","year":"2012","journal-title":"Eur. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000324206","article-title":"High Ki67 Index and Bulky Disease Remain Significant Adverse Prognostic Factors in Patients with Diffuse Large B Cell Lymphoma before and after the Introduction of Rituximab","volume":"126","author":"Gaudio","year":"2011","journal-title":"Acta Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0609.2010.01467.x","article-title":"Ki-67 expression as a prognostic factor in diffuse large B-cell lymphoma patients treated with rituximab plus CHOP","volume":"85","author":"Yoon","year":"2010","journal-title":"Eur. J. Haematol."},{"key":"ref_9","first-page":"837","article-title":"The prognostic role of Bcl-2, Ki67, c-MYC and p53 in diffuse large B-cell lymphoma","volume":"58","author":"Rotaru","year":"2017","journal-title":"Romanian J. Morphol. Embryol. = Revue Roumaine de Morphologie et Embryologie"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1080\/0284186X.2016.1189093","article-title":"A population-based study of cellular markers in R-CHOP treated diffuse large B-cell lymphoma patients","volume":"55","author":"Abdulla","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/modpathol.2011.123","article-title":"Quantitative image analysis in the assessment of diffuse large B-cell lymphoma","volume":"24","author":"Martin","year":"2011","journal-title":"Mod. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1182\/blood-2010-03-276766","article-title":"Immunoblastic morphology but not the immunohistochemical GCB\/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL","volume":"116","author":"Ott","year":"2010","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1080\/10428190802140055","article-title":"Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B-cell lymphoma","volume":"49","author":"Hasselblom","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/ajh.21406","article-title":"Role and prognostic significance of the Ki-67 index in non-Hodgkin\u2019s lymphoma","volume":"84","author":"Broyde","year":"2009","journal-title":"Am. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3109\/10428194.2015.1004169","article-title":"Prognostic effect of Ki-67 expression in rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-treated diffuse large B-cell lymphoma is limited to non-germinal center B-cell-like subtype in late-elderly patients","volume":"56","author":"Koh","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"ref_16","first-page":"e13120","article-title":"Ki67 Proliferation Index in Germinal and Non-Germinal Subtypes of Diffuse Large B-Cell Lymphoma","volume":"13","author":"Hashmi","year":"2021","journal-title":"Cureus"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: A study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.3892\/ol.2017.6577","article-title":"BCL2\/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma","volume":"14","author":"Tang","year":"2017","journal-title":"Oncol. Lett."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/383\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:27:39Z","timestamp":1760167659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,8]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["curroncol28060383"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28060383","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,8]]}}}